NovoMedix, an NCI SBIR-funded company, is a drug discovery company focusing on the discovery and development of new drugs that target unique pathways to provide safer, more effective therapies for life threatening diseases. Our current pipeline contains drugs from three different classes. The lead compounds are novel, orally available, small molecule translation inhibitors that prevent the growth and invasion of cancer cells and also prevent the surrounding stroma from supporting tumor growth. The most advanced drug is undergoing preclinical toxicity and toxicology studies in support of an IND for triple negative breast cancer. We are also developing novel drugs that prevent fibrosis and have demonstrated in vivo efficacy in a mouse transaortic constriction (TAC) model of heart failure. These drugs have a good safety profile and we believe that they will be useful in a wide variety of fibrotic diseases.